


RECEIVED  
CENTRAL FAX CENTER

FEB 05 2007

TELECOPIER TRANSMISSIONTO: USPTO FAX NO.: (571) 273-8300FROM: James V. CostiganTOTAL NO. OF PAGES INCLUDING THIS COVER SHEET: 3 pagesDATE: February 5, 2007 CHARGE: 1259-001

RE: Serial No.09/854,802

(IF THERE ARE ANY PROBLEMS REGARDING THIS TRANSMISSION,  
PLEASE CALL (212) 302-8989)CONFIDENTIALTHE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY BE SUBJECT  
TO THE ATTORNEY-CLIENT PRIVILEGE OR ATTORNEY WORK PRODUCT EXCLUSION.THIS FACSIMILE IS ONLY INTENDED FOR THE DESIGNATED RECIPIENT(S). ANY RECIPIENT OTHER  
THAN THE DESIGNATED RECIPIENT(S) IS HEREBY NOTIFIED THAT ANY DISCLOSURE OR USE OF THE  
INFORMATION IS UNAUTHORIZED AND PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN  
ERROR, PLEASE NOTIFY: HEDMAN & COSTIGAN, P.C. BY TELEPHONE AT (212) 302-8989REMARKS: ☐ Urgent ☐ For Your Review/Comments ☐ Reply ASAP ☐ FYI  
☐ Per Your Request Original ☐ will / ☐ will not followCertificate of TransmissionI hereby certify that this correspondence (REPLY BRIEF 2pages) for Application Serial  
No. 09/854,802 is being facsimiled to the U.S. Patent & Trademark Office via fax  
number. (571) 273-8300 on the date shown below.  
James V. Costigan, Reg. No. 25,669

February 5, 2007

RECEIVED  
CENTRAL FAX CENTER  
FEB 05 2007

Docket No.: 1259-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Bojidar M. Stankov ) Group Art: 1616  
Serial No.: 09/854,802 ) Examiner: Choi, Frank I.  
Filed: May 14, 2001 )

For: CONTROLLED RELEASE FORMULATIONS CONTAINING AN ACTIVE  
INGREDIENT, PREFERABLY MELATONIN AND THE METHOD OF PREPARATION

New York, NY 10036  
February 5, 2007

MS Appeal  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

REPLY BRIEF

The Examiner is urging that the portion of the specification that points out that since 95% of the melatonin was released "within the 5th hour" and not --within five hours--, the specification is not enabling. The specification is addressed to one of ordinary skill in the art of controlled release pharmaceuticals and it is well known that all measurements of controlled released products are based on a cumulative total of release active ingredient after a specified time. The language of the specification would have to require that release was "after the fourth hour and only during the fifth hour" in order to convey the meaning that the Examiner has ascribed to the present specification.


The specification at page 9, lines 24-29 described how the release test were carried out: "samples from the supernatant were taken out at predetermined times: 1, 5, 10, 30minutes and 1, 2, 3, 4, 5 and 6 hours" This information must be considered in connection with the reference to the fifth hour that the Examiner has cited. In the Lee et al., J. of Pharmaceutics 188 (1999) 71-80 citation which was cited by the

Examiner, a typical release curve appears which shows that the release vs. time is computed cumulatively and is not based on a release within any period of time within the middle of the test.

The Examiner's comments regarding the failure of the claims to recite "essential elements" fail to acknowledge that the reference to the "omitted elements" was a reference to "Stages" in the preparation of the claimed products. It is not necessary to recite processing information that is disclosed in a specification as an optimum method of making a particular product.

For these reasons, and the reasons set forth in the BRIEF, it is requested that the rejections of record be reversed.

Respectfully submitted,

  
James V. Costigan  
Reg. No. 25,669

**MAILING ADDRESS:**

HEDMAN & COSTIGAN, P.C.  
1185 Avenue of the Americas  
New York, NY 10036-2601  
(212) 302-8989